Sakar Healthcare Limited

NSE SAKAR.NS

Sakar Healthcare Limited Free Cash Flow Yield on February 07, 2025: -6.09%

Sakar Healthcare Limited Free Cash Flow Yield is -6.09% on February 07, 2025, a -14.10% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.
  • Sakar Healthcare Limited 52-week high Free Cash Flow Yield is -4.44% on April 08, 2024, which is 27.17% above the current Free Cash Flow Yield.
  • Sakar Healthcare Limited 52-week low Free Cash Flow Yield is -6.60% on March 13, 2024, which is -8.24% below the current Free Cash Flow Yield.
  • Sakar Healthcare Limited average Free Cash Flow Yield for the last 52 weeks is -5.25%.
Key data
Date Free Cash Flow Yield Market Value Added (MVA) Price to Book Ratio (P/B) Price to Earnings Ratio (P/E)
Market news
Loading...
SV Wall Street
NSE: SAKAR.NS

Sakar Healthcare Limited

CEO Mr. Sanjay Surendra Shah
IPO Date March 16, 2017
Location India
Headquarters 406, Silver Oaks Comm. Complex
Employees 325
Sector Healthcare
Industries
Description

Sakar Healthcare Limited research, develops, manufactures, and markets pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectable SVP in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in approximately 22 therapeutic areas, such as antacid, antimalerial, anticoagulant, laxative, anthelmintic, bronchodilator, anaesthetic, antidepressant, sedative, adrenergic, anti-infective, diuretics, oxytocic, analgesic, antiemetic, antipsychotic, antifungal, PPI, anticonvulsant, anti-inflammatory, antihistamine, and multi vitamins. The company also exports its products to approximately 38 countries, including Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. Sakar Healthcare Limited was incorporated in 2004 and is based in Ahmedabad, India.

StockViz Staff

February 8, 2025

Any question? Send us an email